MDLZ Rallies on Q1 Beat as Cocoa Eases, But DeepValue Flags Broader Headwinds

What happened

Mondelez reported a Q1 2026 earnings beat that sent shares sharply higher, driven by early signs that record cocoa costs are finally easing and benefitting the bottom line. The MarketBeat article notes that at 32x trailing earnings the stock doesn't look like a value play, but forward earnings of ~20x suggest potential for multiple compression if recovery materializes. However, the latest DeepValue master report, which assigns a WAIT rating with an attractive entry near $47, underscores that the earnings pressure is broader than just cocoa—global volume/mix remained deeply negative at –4.6% in Q3 2025, and tariffs, labor, and other input costs still weigh. Management's own guidance cut to –15% adjusted EPS in 2025 shows they underestimated the breadth of headwinds, and the stock's current ~20x forward P/E already prices in a high‑single‑digit EPS recovery that may prove optimistic. Until there is clearer evidence that volumes are stabilizing and gross margin is inflecting, the risk‑reward from today's level remains balanced, favoring disciplined investors who wait for either a lower entry or concrete proof of margin repair.

Implication

Investors should wait for tangible evidence that global volumes are recovering and gross margins are heading back above 35% before committing new capital. The implied EPS growth in the current price assumes a clean recovery that may fall short given structural cost and demand challenges. A re-assessment window of 6-12 months allows confirmation of margin inflection.

Thesis delta

The thesis has shifted from a pure cocoa‑driven margin rebound story to a more nuanced recovery where volume/mix and broader input costs (tariffs, labor, other commodities) could limit EPS growth to low‑single digits rather than the high‑single‑digit expectation baked into the stock. While cocoa relief is real, it may not be sufficient to restore margins to pre‑shock levels if elasticity and consumer down‑trading persist. This reduces confidence in the 2026‑27 earnings recovery trajectory and supports a WAIT stance until fundamentals clearly improve.